Vincent Ribrag
Impact in
- Pathology and Forensic Medicine top 0.05%
- Lymphoma Diagnosis and Treatment
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Viral-associated cancers and disorders
Papers in
-
- Lymphoma Diagnosis and Treatment 226
- Oncology 170
- Viral-associated cancers and disorders 55
- CAR-T cell therapy research 50
- Cancer Immunotherapy and Biomarkers 36
- Co-authors
- Jean‐Marie Michot (84 shared papers)Pier Luigi Zinzani (35 shared papers)Craig H. Moskowitz (19 shared papers)Philippe A. Armand (20 shared papers)Margaret Ann Shipp (18 shared papers)Arun Balakumaran (16 shared papers)Alejandro Daniel Ricart (6 shared papers)Jean‐Charles Soria (33 shared papers)
- Journals
- Blood (87 papers)European Journal of Cancer (23 papers)Annals of Oncology (22 papers)Hematological Oncology (18 papers)Journal of Clinical Oncology (16 papers)
- Partner nations
- FranceUnited StatesGermany
In The Last Decade
Vincent Ribrag
411 papers receiving 17.8k citations
Vincent Ribrag's Hit Papers
Peers
Comparison fields: 5 of 130
- Pathology and Forensic Medicine 7.8k
- Oncology 9.1k
- Genetics 3.7k
- Hematology 1.9k
- Immunology 2.8k
Countries citing papers authored by Vincent Ribrag
This map shows the geographic impact of Vincent Ribrag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent Ribrag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent Ribrag more than expected).
Fields of papers citing papers by Vincent Ribrag
This network shows the impact of papers produced by Vincent Ribrag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent Ribrag. The network helps show where Vincent Ribrag may publish in the future.
Co-authors
The 25 scholars most cited alongside Vincent Ribrag, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 419 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Immune-related adverse events with immune checkpoint blockade: a comprehensive review Hit paper breakdown → | 2016 | 1785 |
| 2 | Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma Hit paper breakdown → | 2017 | 818 |
| 3 | High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial Hit paper breakdown → | 2017 | 597 |
| 4 | Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure Hit paper breakdown → | 2016 | 561 |
| 5 | Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study Hit paper breakdown → | 2018 | 512 |
| 6 | Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial Hit paper breakdown → | 2020 | 460 |
| 7 | Treatment of Older Patients with Mantle-Cell Lymphoma Hit paper breakdown → | 2012 | 402 |
| 8 | Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network Hit paper breakdown → | 2016 | 313 |
| 9 | Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma Hit paper breakdown → | 2017 | 312 |
| 10 | Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma Hit paper breakdown → | 2018 | 288 |
| 11 | 2016 | 279 | |
| 12 | 2019 | 270 | |
| 13 | 2016 | 262 | |
| 14 | 2001 | 257 | |
| 15 | 2017 | 253 | |
| 16 | 2018 | 229 | |
| 17 | 2009 | 223 | |
| 18 | 2019 | 220 | |
| 19 | 2012 | 216 | |
| 20 | 2019 | 215 |
About Vincent Ribrag
Vincent Ribrag is a scholar working on Pathology and Forensic Medicine, Oncology, Genetics, Hematology and Cancer Research, having authored 419 papers that have together received 18.2k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (226 papers), Chronic Lymphocytic Leukemia Research (76 papers), Viral-associated cancers and disorders (55 papers), CAR-T cell therapy research (50 papers), Cancer Immunotherapy and Biomarkers (36 papers), CNS Lymphoma Diagnosis and Treatment (29 papers), Cancer Genomics and Diagnostics (26 papers) and Multiple Myeloma Research and Treatments (23 papers). The work is most often cited by research in Pathology and Forensic Medicine (7.8k citations), Oncology (9.1k citations), Genetics (3.7k citations), Hematology (1.9k citations) and Immunology (2.8k citations). Vincent Ribrag has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Jean‐Marie Michot, Pier Luigi Zinzani, Craig H. Moskowitz, Philippe A. Armand, Margaret Ann Shipp, Arun Balakumaran, Alejandro Daniel Ricart, Jean‐Charles Soria, Pauline Brice and John G. Kuruvilla. Their work appears in journals such as Blood, European Journal of Cancer, Annals of Oncology, Hematological Oncology and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.